Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 16/20 | 0.66 |
| ▸ | RARG | P13631 | 16/20 | 0.66 |
| ▸ | RARA | P10276 | 14/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 3/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30061258 | 1.00 | RARB (0.66) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9333999 | 0.92 | RARB (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8037152 | 0.89 | RARA (0.52) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9318560 | 0.86 | RARB (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6914287 | 0.82 | RARB (0.58) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6445988 | 0.80 | RARB (0.44) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL19342986 | 0.80 | RARB (0.62) | RARBRARGRARACYP3A4CYP26A1 | |
| Tazarotenic Acid SCHEMBL29466098 | 0.80 | CYP3A4 (1.00) | RARBRARGRARACYP3A4CYP26A1 | |
| Tazarotenic Acid SCHEMBL678713 | 0.80 | CYP3A4 (1.00) | RARBRARGRARACYP3A4CYP26A1 | |
| Tazarotenic Acid SCHEMBL29433140 | 0.80 | CYP3A4 (1.00) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006059345-A2 | PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-06-08 | — | — | WO | claimed |
| EP-0804194-B1 | USE OF RETINOIC ACID RECEPTOR-AGONISTS OR AP-1 ANTAGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING PROLIFERATION OF RETINAL PIGMENT EPITHELIUM | UNIV JOHNS HOPKINS MED (US) | 2005-03-30 | — | — | EP | claimed |
| US-20020128291-A1 | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists | ALLERGAN, CALIFORNIA CORPORATION | 2002-09-12 | — | — | US | claimed |
| US-20020022047-A1 | Implant device with a retinoid for improved biocompatibility | ALLERGAN, INC. | 2002-02-21 | — | — | US | claimed |
| US-6114348-A | Method of treating warts using tazarotene | PEARL I, LLC | 2000-09-05 | — | — | US | claimed |
| US-6110485-A | INCLUDES A THERAPEUTICAL AGENT AND RETANOID ALONG WITH A CARRIER SIZED FOR INSERTION INTO EYE TISSUE IN WHICH THE SYSTEMIC RELEASE OF A THERAPEUTICAL AGENT IS DESIRED FOR PROVIDING SUSTAINED OR CONTROLLED RELEASE OF THE DRUG | ALLERGAN SALES, INC. (US) | 2000-08-29 | — | — | US | claimed |
| EP-0284288-B1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1992-05-27 | — | — | EP | claimed |
| CN-110121331-B | Personal care compositions containing poorly soluble compounds | 联合利华知识产权控股有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-3080142-B1 | GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF | SUSSEX RES LABORATORIES INC (CA) | 2018-01-31 | — | — | EP | disclosed |
| US-9856290-B2 | Glycopeptide compositions and uses thereof | SUSSEX RESEARCH LABORATORIES INC. (CA) | 2018-01-02 | — | — | US | disclosed |
| US-20160304561-A1 | GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF | SUSSEX RESEARCH LABORATORIES INC. (CA) | 2016-10-20 | — | — | US | disclosed |
| EP-3080142-A1 | GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF | Sussex Research Laboratories Inc. (CA) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015085421-A1 | GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF | SUSSEX RESEARCH LABORATORIES INC. (CA) | 2015-06-18 | — | — | WO | disclosed |
| US-20020022047-A1 | Implant device with a retinoid for improved biocompatibility | ALLERGAN, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6306426-B1 | Implant device with a retinoid for improved biocompatibility | ALLERGAN SALES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6110485-A | INCLUDES A THERAPEUTICAL AGENT AND RETANOID ALONG WITH A CARRIER SIZED FOR INSERTION INTO EYE TISSUE IN WHICH THE SYSTEMIC RELEASE OF A THERAPEUTICAL AGENT IS DESIRED FOR PROVIDING SUSTAINED OR CONTROLLED RELEASE OF THE DRUG | ALLERGAN SALES, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6074661-A | Sterile bioerodible occular implant device with a retinoid for improved biocompatability | ALLERGAN SALES, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0969847-A1 | TAZAROTENE AND CORTICOSTEROID TREATMENT FOR PSORIASIS | Allergan Sales, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998036753-A1 | TAZAROTENE AND CORTICOSTEROID TREATMENT FOR PSORIASIS | ALLERGAN SALES,INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RARB 13/4885RARG 10/4885RARA 21/4885 |
| US-20160304561-A1 | GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF | FUT6, FUT5, ST3GAL3 | RARB 4813/4885RARG 4634/4885RARA 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.